Wanida

😍 #ThankYou ... 💃🏽🪩

🧘🏽‍♀️The art of living ... #Vipassana #Meditation bbc.com/audio/play/w3c…

😻 Cats have entered the #GLP-1 era. 🚀Naturally, they need #CatMap. 🐈✨ cnbc.com/2026/07/18/cat…

🚀 #BatMap by @bodymapdigital linkedin.com/posts/metaboli…

🌏 Earth remains my favorite habitat. 🏡 ☀️ Sunshine, the ocean, and gravity. 🌊 🚀 Space? ... My mitochondria definitely won't be happy 🧬 nature.com/articles/d4158…

🥳 Product Portfolio ...😻 Off you go, little ones 💅

🎉 one body … ❤️ one system

🌸#BiologicalAge .... 🎯Where is the peak? linkedin.com/posts/wanida-c…

⏰ body clock ... 📅

@MichaelOkun 💐 Preclinical Phase -> what’s happening there 💡

Multiple sclerosis is entering a new era: from controlling relapses to preventing progression. Progression independent of relapse activity means that disability can slowly accumulate even when there are no obvious attacks or new MRI lesions. This concept is reshaping how we think about multiple sclerosis (MS). Hauser describes in a new review paper in the The New England Journal of Medicine how our understanding of MS has evolved from a disease defined by relapses to one driven by both inflammation and neurodegeneration. Key points: - Epstein-Barr virus infection has emerged as one of the strongest environmental risk factors linked to MS development. - Highly effective B cell therapies targeting CD20 can reduce new inflammatory lesions by approximately 99% and have transformed outcomes for relapsing MS. - Despite these remarkable advances, silent progression and neurodegeneration continue in many individuals and these remain the field's greatest unmet challenge. My take: This review captures one of the most important shifts in modern neurology. For years we celebrated preventing relapses and reducing MRI lesions. Those victories matter tremendously. However, the next frontier will be preventing progression, preserving brain reserve and repairing myelin before disability accumulates. Here are 5 points that resonated w/ me: 1- MS is increasingly being understood as a disease that begins years before the first symptom appears. 2- The story of MS has evolved from a T cell disease to one where B cells occupy center stage. 3- Early use of highly effective therapies may alter the long-term trajectory of the disease. 4- Relapse control alone is no longer enough, and future therapies must tackle neurodegeneration and myelin repair. 5- The future of MS care will likely combine precision biomarkers, imaging, immune therapies and regenerative strategies aimed at keeping folks functioning and thriving for decades. nejm.org/doi/full/10.10… #MS #multiplesclerosis

🎯 The cocktail of #BodyFat ... #BAT <-> #WAT... 🤟🏽white, beige and brown!

@AgingBiology 👸🏽 Perfect 👌 … That’s my estimation too 💡🥳

How long can humans live? All evidence points to a maximum of 125 years nature.com/articles/d4158…

⏲️ "Nonlinearity of aging" ... #BiologicalAge era is here! 🔖 Review article by @EricTopol - "the field of biological clocks" @Nature 👇🏽

🤩Cognitive shuffling ... 😴 Refocusing on something that’s going to be boring as opposed to stimulating 😳🐑 time.com/article/2026/0…

🧠 The cocktails of 'life' .... Human 'being' is a masterpiece architecture 💟

🌤️ J-Space ... (Neuro) Diversity for Working & Dreaming Space

🧚🏽‍♀️ “The self is an illusion.” 🌞🌤️🌥️ We are not the same across time. 💗Biology + philosophy ... continuity without permanence 🌱🍃 bigthink.com/mini-philosoph…

@agingdoc1 🧠 high price tag 💡

Alzheimer's disease drug development pipeline: 2026 "There are 158 drugs for the treatment of Alzheimer's disease in the 2026 drug development pipeline.... 73% of drugs in the pipeline are disease targeted therapies whose goal is to slow disease progression... A diverse array of AD pathophysiological processes is being addressed by drugs in trials." alz-journals.onlinelibrary.wiley.com/doi/10.1002/tr…

👸🏽 Magic ✨ ... 'Universe' = ?

🧚🏽‍♀️ #Sleep tight and don't let the bed bugs bite 😴 🌸The best anti-ageing treatment is still free. #BioAge @Nature